Cutaneous lesions and clinical outcomes in five cats after frunevetmab injections.

Case Series Summary: This case series describes five cats with cutaneous adverse events after subcutaneous administration of frunevetmab, a felinised anti-nerve growth factor monoclonal antibody, including histopathological findings in one case. All cats displayed moderate to severe pruritus resulting in self-trauma to the neck and/or head, causing lesions ranging from superficial dermatitis to alopecia and ulcerations. There were no reactions at the injection sites.

Cerebral pyogranulomatous encephalitis caused by in a 15-week-old domestic shorthair kitten.

Case Summary: A case of cerebral phaeohyphomycosis caused by is described in a 15-week-old domestic shorthair kitten.

Relevance And Novel Information: Cerebral phaeohyphomycosis is a rare condition in cats caused by dematiaceous fungi. This report describes the clinical and histopathological findings in the youngest case documented in a feline, provides a brief review of aetiology, diagnosis, treatment and prognosis of cerebral phaeohyphomycosis and demonstrates the importance of molecular diagnostics in accurate mycotic species identification.

Periodic hypokalaemic polymyopathy in Burmese and closely related cats: a review including the latest genetic data.

Global Importance: Hypokalaemic polymyopathy is a genetic disease of Burmese cats that has been encountered in Australasia, Europe and South Africa.

Clinical Features: Affected cats usually present with signs of muscle weakness and muscle pain in the first year of life. Although certain clinical features, such as ventroflexion of the head and neck, are especially characteristic, some cats do not display these signs.

Intramuscular glargine with or without concurrent subcutaneous administration for treatment of feline diabetic ketoacidosis.

Objective: To describe treatment response and outcome in 15 cats with diabetic ketoacidosis (DKA) initially stabilized with glargine administered intramuscularly (IM) with or without subcutaneous (SC) glargine.

Materials And Methods: Fifteen cats diagnosed with DKA were initially administered IM glargine (1-2 U) and in most cats (12/15 cats) this was combined with SC glargine (1-3 U). This was followed by intermittent IM glargine as required at intervals of 2 or more hours (range 2-22 h) and SC glargine (1-2 U) every 12 hours.

Long-term safety, efficacy and palatability of oral meloxicam at 0.01-0.03 mg/kg for treatment of osteoarthritic pain in cats.

Osteoarthritis is a chronic, painful condition that is now recognised as affecting a large proportion of cats. Non-steroidal anti-inflammatory drugs (NSAIDs) have proven efficacy in dogs and humans but there are limited published data on the use of NSAIDs in the long-term management of this condition in cats. This prospective study aimed to assess the long-term safety and palatability of oral meloxicam and its efficacy in treating osteoarthritic pain in cats when given at a dose of 0.